



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Patrick CHATON, et al.

GAU: 1634

SERIAL NO: 10/089,164

EXAMINER:

FILED: March 27, 2002

FOR: METHOD AND DEVICE FOR DETECTING A MOLECULAR RECOGNITION REACTION

## REQUEST FOR PRIORITY

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

- ☐ Full benefit of the filing date of U.S. Application Serial Number \_\_\_\_\_, filed \_\_\_\_\_, is claimed pursuant to the provisions of 35 U.S.C. §120.
- ☐ Full benefit of the filing date(s) of U.S. Provisional Application(s) is claimed pursuant to the provisions of 35 U.S.C. §119(e):
- | <u>Application No.</u> | <u>Date Filed</u> |
|------------------------|-------------------|
|------------------------|-------------------|

- ☒ Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.


In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

| <u>COUNTRY</u> | <u>APPLICATION NUMBER</u> | <u>MONTH/DAY/YEAR</u> |
|----------------|---------------------------|-----------------------|
| France         | 99 12229                  | September 30, 1999    |

Certified copies of the corresponding Convention Application(s)

- ☒ are submitted herewith
- ☐ will be submitted prior to payment of the Final Fee
- ☐ were filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_
- ☐ were submitted to the International Bureau in PCT Application Number \_\_\_\_\_  
Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.
- ☐ (A) Application Serial No.(s) were filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_; and
- ☐ (B) Application Serial No.(s) \_\_\_\_\_
- ☐ are submitted herewith
- ☐ will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon
  
 Kirsten A. Gruneberg, Ph.D.  
 Registration No. 47,297

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)



☐ Technique - Web  
☒ Médical - Pharmaceutique

Aéronautique ☐ Automobile

Technique - Marketing  
Commercial - Marketing ☒

## DECLARATION

I, Mrs. MCKEAG, of A.R.T International BP 18 95410 GROSLAY France

do hereby declare that I am conversant with the English and French languages and am a competent translator thereof.

I declare further that the following is a true and accurate translation into English of the French Patent Application N° 99 12229 filed on September 30, 1999.

Signed this 20th day of February 2004



B.P. 18  
95410 GROSLAY  
Tél : 01.39.34.70.70  
Fax : 01.39.34.70.77

INPI  
Institut National de  
la Propriété Industrielle<sup>1</sup>

**PATENT**

**CERTIFICATE OF UTILITY - CERTIFICATE OF ADDITION**

**OFFICIAL COPY**

The Director General of *Institut national de la Propriété Industrielle*<sup>1</sup> certifies that the document appended hereto is a certified true copy of an application for a certificate of patent rights filed with this office.

Issued in Paris, on: ..... 12 FEB 2004

Signed: Martine PLANCHE  
Head of Patent Division

on behalf of the General Director  
*Institut National de la Propriété Industrielle*<sup>1</sup>

|              |                                  |
|--------------|----------------------------------|
| INSTITUT     | Head Office                      |
| NATIONAL DE  | 26 bis, rue de Saint Pétersbourg |
| LA PROPRIETE | 75800 PARIS Cedex 08             |
| INDUSTRIELLE | Telephone : 33 (1) 53 04 53 04   |
|              | Fax: 33 (1) 53 04 45 23          |

---

<sup>1</sup> French Patent Office

26 bis, rue de Saint Pétersbourg  
75800 Paris Cedex 08  
Telephone 01 53 04 53 04 - Fax

Code of Intellectual Property Rights – Book VI

**PATENT *cerfa* n° 11354\*01**  
**CERTIFICATE OF UTILITY**

### APPLICATION FOR ISSUE OF CERTIFICATE

### Filing confirmation by fax

Form to be filled in legibly using black ink

| <p>Space reserved for the INPI office</p> <p><b>SUBMISSION OF DOCUMENTS:</b></p> <p>DATE : <b>30 SEPT 1999</b></p> <p>NATIONAL REGISTRATION NUMBER: <b>9912229</b></p> <p>FILING DEPARTMENT: <b>75 INPI PARIS</b></p> <p>DATE OF FILING:</p>  |                  | <p><b>1. NAME AND ADDRESS OF APPLICANT OR AGENT TO WHOM CORRESPONDENCE IS TO BE SENT</b></p> <p><b>BREVATOME</b><br/> 3, rue du Docteur Lancereaux<br/> 75008 PARIS</p> <p>permanent power ref refs of correspondent telephone<br/> 7068 of 12.06.98 B 13324.3/EE 01 53 83 94 00</p> <p><b>Initial application for patent DD1943/BIOMERIEUX</b></p> <p>▼</p> <p><input type="checkbox"/> Patent application <input type="checkbox"/> Certificate of utility no. date</p> |                   |                   |        |             |                  |   |                  |                                  |                   |
|---|------------------|--|-------------------|-------------------|--------|-------------|------------------|---|------------------|----------------------------------|-------------------|
| <p><b>2. TYPE OF APPLICATION</b></p> <p><input checked="" type="checkbox"/> Patent application <input type="checkbox"/> Divisional application</p> <p><input type="checkbox"/> Certificate of utility <input type="checkbox"/> Conversion of a</p> <p style="padding-left: 100px;">European patent application</p> <p><b>RESEARCH REPORT</b> <input type="checkbox"/> differed <input checked="" type="checkbox"/> immediate</p> <p>The applicant, an individual, requires payment of fees in installments <input type="checkbox"/> yes <input type="checkbox"/> no</p>   |                  |  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>TITLE OF INVENTION (no more than 200 characters or spaces)</b></p> <p><b>METHOD AND DEVICE FOR DETECTING A MOLECULAR RECOGNITION REACTION</b></p>   |                  |  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>3 APPLICANT(s)</b> SIREN No.</p> <p>Name and first names (underline surname) or company name</p>  |                  | <p>APE-NAF code</p> <p>Legal form</p>  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>COMMISSARIAT A L'ENERGIE ATOMIQUE</b></p> <p>Public undertaking with a scientific, technical and industrial nature</p> <p><b>BIOMERIEUX S.A.</b></p> <p>Limited liability company</p> <p>Nationality (ies) French</p> <p>Full address(es)</p> <p style="padding-left: 40px;">31, 33 rue de la Fédération<br/> 75752 PARIS 15<sup>th</sup> arrdt.</p> <p style="padding-left: 40px;">Chemin de l'Orme<br/> 69280 MARCY L'ETOILE</p> <p style="text-align: right;">Country</p> <p style="text-align: right;">France</p> <p style="text-align: right;">France</p> <p style="text-align: right;">If more space needed, continue on a separate sheet</p> |                  |  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>4 INVENTOR(S)</b> The inventors are the applicants <input type="checkbox"/> yes <input checked="" type="checkbox"/> no In this case provide a separate inventor designation</p>   |                  |  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>5 REDUCTION IN FEE RATE</b> <input type="checkbox"/> Requested for the first time <input type="checkbox"/> Requested prior to this filing</p> <p style="text-align: right;"><i>(enclose a copy of decision granting reduction)</i></p>  |                  |  |                   |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>6 STATEMENT OF PRIORITY OR REQUEST TO BENEFIT FROM FILING DATE OF A PRIOR FRENCH APPLICATION</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">country of origin</th> <th style="width: 25%;">number</th> <th style="width: 25%;">filing date</th> <th style="width: 25%;">application type</th> </tr> </thead> <tbody> <tr> <td>7</td> <td><b>DIVISIONS</b></td> <td>prior to the present application</td> <td>no. date no. date</td> </tr> </tbody> </table>  |                  |  |                   | country of origin | number | filing date | application type | 7 | <b>DIVISIONS</b> | prior to the present application | no. date no. date |
| country of origin   | number           | filing date  | application type  |                   |        |             |                  |   |                  |                                  |                   |
| 7   | <b>DIVISIONS</b> | prior to the present application   | no. date no. date |                   |        |             |                  |   |                  |                                  |                   |
| <p><b>8 SIGNATURE OF APPLICANT OR AGENT</b></p> <p>(name and capacity of signatory)</p> <p>M. DES TERMES</p> <p>422-5/S002 [signature]</p>  |                  | <p><b>OFFICIAL SIGNATURE ON RECEIPT</b></p> <p><b>SIGNATURE ON REGISTRATION OF THE APPLICATION AT THE INPI</b></p> <p style="text-align: right;">[signature]</p>   |                   |                   |        |             |                  |   |                  |                                  |                   |

**INPI**  
PATENT DEPARTMENT  
26 bis, rue de Saint Pétersbourg  
75800 Paris Cedex 08  
Telephone 01 53 04 53 04 - Fax 01 42 93 59 30

**B 13324.3 EE**

**PATENT CERTIFICATE OF UTILITY**

**DESIGNATION OF THE INVENTOR**  
(if the applicant is not the inventor or the sole inventor)

**NATIONAL REGISTRATION NUMBER**  
**99 12229 dated 30.09.99**

**TITLE OF THE INVENTION**

**METHOD AND DEVICE FOR DETECTING A MOLECULAR RECOGNITION REACTION**

**THE UNDERSIGNED**

**M. DES TERMES**  
**c/o BREVATOME**  
**3, rue du Docteur Lancereaux**  
**75008 PARIS**

**DESIGNATE AS INVENTOR(S)** (state surname, first names, address and underline surname):

**CHATON Patrick**

**"Loutre"**  
**38570 THEYS**

**POUPINET Ludovic**

**162, Avenue Victor Hugo**  
**38170 SEYSSINET**

**GINOT Frédéric**

**55, rue du Général Leclerc**  
**38340 VOREPPE**

**NOVELLI ROUSSEAU Armelle**

**29 rue du Parc**  
**38180 SEYSSINS**

**FRANCE**

**NB.** By way of exception, the name of the inventor may be followed by that of the company to which he is attached when the latter differs from the applicant or proprietary company

**Date and signature(s) of the applicant(s) or agent**

**PARIS 11 OCTOBER 1999**

**[signature]**

**M. DES TERMES**  
**422-5/S002**

## DOCUMENT COMPRISING MODIFICATIONS

| PAGES OF DESCRIPTION OR CLAIMS OR DRAWINGS |         |       | CM* | DATE OF CORRESPONDENCE | DATE STAMP OF CORRECTOR |
|--|---------|-------|-----|------------------------|-------------------------|
| Modified                                   | Deleted | Added |     |                        |                         |
| Page 51                                    |         | 14    | X   | 11-01-00               | 14-01-00                |
| 53   | 54      |       | X   | 27-10-01               | 17-01-02                |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |
|  |         |       |     |                        |                         |

Any change made to the wording of the original claims, unless arising out of the provisions of article R612-36 of the Intellectual Property Code, is indicated by the initials CM (claims modified)

METHOD AND DEVICE FOR DETECTING A MOLECULAR RECOGNITION  
REACTION

Technical field of the invention

The present invention relates to a method for detecting a molecular recognition reaction without any labelling, and to a device for implementing this method.

5        This invention relates to the general field of detection and analysis of a molecular recognition between a first and second molecule, for example in molecular biology.

      According to the invention, molecular recognition  
10 may be defined as a specific interaction between more or less complex molecules, leading to a sufficiently stable bond of both molecules so that the molecules may be detected as bound molecules. For example, this may be a hybridization of nucleic acids (DNA and/or RNA),  
15 with a recognition reaction of the type antigen/antibody, an interaction of the protein/protein type, an interaction of the enzyme/substrate type, etc... The molecules relevant to the present invention are therefore those that are involved in the  
20 aforementioned interactions.

      With the method of the present invention, this type of molecular recognition wherein one of the two or both molecules are fixed on a solid support, may be detected by detecting a change in absorption by a  
25 photothermal method.

      This method notably finds application in the detection of the hybridization of nucleic acids on a

solid support, in an aqueous medium or in air, for example within the framework of a screening or of a detection of hybridization on a biochip.

5    State of the art

For example, detection of nucleic acid hybridization is generally performed by means of labelling with a fluorescent molecule. However, this type of detection requires the use of several chemical  
10 reagents, and leads to a high cost and a long processing period. Further, techniques that utilize fluorescence are not always very accurate. Finally, at least one molecule is modified by the labelling; this may affect the molecular recognition reaction.

15    Also, other methods have been suggested, for example optical methods consisting in detecting thickness or index changes in a sample, for example by ellipsometry, photogoniometry or by resonance methods.

However, in the case of oligonucleotides on a  
20 solid support, for example, the formed layers are ultrafine, from a few angströms to a few nanometers thick, so that the detection of thickness or index changes requires extremely sensitive and expensive laboratory apparatus.

25

Discussion of the invention

Specifically, the object of the present invention is to provide a new detection technique without any labelling, for a molecular recognition reaction between  
30 a first molecule, a so-called capture molecule, fixed



on a solid support, and a second molecule, a so-called target molecule, present in a solution to be tested.

The method of the invention is characterized in that the detection is performed by a photothermal  
5 method.

According to the invention, the recognition reaction as well as the first and second molecules may be the aforementioned ones.

When the first and the second molecules are nucleic  
10 acid molecules, the method of the invention, for example, may comprise the following steps:

- fixation of the first nucleic acid molecule on a solid support,
- contacting of the first molecule of nucleic acid  
15 fixed on the solid support with a solution to be tested, suspected of comprising the second nucleic acid molecule, the latter being capable of hybridizing to said first molecule, the contacting being carried out under conditions favourable to said hybridization,
- 20 - washing of the solid support in order to isolate a measurement sample consisting of said first molecule fixed on the support and optionally of said second molecule hybridized on the first molecule, and
- measurement of the absorption of the sample by a  
25 photothermal method.

In addition, the method of the present invention may comprise a step for comparing the measurement of the absorption of the predefined measurement sample, with that of a control sample, a so-called calibration  
30 sample, the absorption of which is a known measure.

The first molecule, fixed on the support, may also be called a capture molecule and the second molecule, present in the solution to be tested, may also be called a target molecule. It may also be called a  
5 "probe" when this is a DNA molecule fixed on the support.

It is important to note that thin nucleic acid layers whether hybridized or not, are usually considered as non-absorbing. This is notably described  
10 in "Ellipsometric and interferometric characterization of DNA probes immobilized on a combinational assay", Gray et al., Langmuir 1997, 13, 2833-2842.

In spite of this, the present inventors were interested in photothermal methods applied to the  
15 detection and analysis of a molecular recognition reaction.

All these methods have in common, the excitation of the sample, the absorption of which should be measured by a light source, called the pump beam,  
20 generally a laser. A portion of the incident light energy is absorbed by the sample. The proportion of absorbed energy is set by the absorption spectrum of the sample and the emission spectrum of the excitation source. A portion of the absorbed energy is transformed  
25 into heat. The remainder may be radiated or give rise to fluorescence or to a chemical reaction, for example. The heat induces a change in temperature in the absorbing medium and in the adjacent media, the change in temperature may also be expressed by a change in  
30 density and therefore in index, or by a change in pressure, or by the occurrence of an acoustical wave.

The rise in temperature due to absorption is generally inhomogeneous, and therefore gives rise to an index gradient of the analyzed medium and of the adjacent media, whereby the density of the media is made  
5 inhomogeneous by the rise in temperature.

Photothermal methods consist in measuring the effects induced by the absorption.

The inventors have demonstrated that among the photothermal methods, the photothermal deflection  
10 method and the thermal lens method may for example be used according to the present invention.

The photothermal deflection method is a method which consists in measuring the deviation of a light beam, called the probe beam, passing in the area where  
15 the index gradient is to be found. In other words, it consists in measuring the deviation of the probe beam due to the heating of an absorbing sample via the pump beam. This photothermal deflection technique has been applied to surface analysis such as absorption mapping,  
20 thermal parameter imaging, but never for detecting molecular recognition as defined above.

The thermal lens method as to itself consists in measuring the change in the focussing of a light beam passing in the area where the index gradient is to be  
25 found.

A full presentation of photothermal methods may be found for example in the textbook "Photothermal Spectroscopy Methods for Chemical Analysis, S.E. Bialkowski, vol. 134 in Chemical Analysis: a Series of  
30 Monographs on Analytical Chemistry and its Applications, Wiley".

According to the method of the invention, the solid support may be defined as a support on which the first molecule may be chemically fixed directly or indirectly. Preferably, the support has low absorption  
5 as compared to that of the sample placed at its surface so as not to interfere with photothermal detection. Moreover, it preferably has low thermal conductivity since a too large conductivity of the support induces wide distribution of the heat, therefore a lowering of  
10 the temperature gradient and a lowering of the detected signal.

According to the invention, this support may for example be a support which is used in the manufacturing of DNA chips, for example a silica, glass or plastic  
15 support. It is also possible to work with semiconductors, by coating their surface with dielectric layers in order to improve the signal to noise ratio.

According to the invention, the first so-called  
20 capture molecule is fixed on the support. This fixation of the first molecule on the support may be achieved by conventional chemical reactions well known to one skilled in the art, and selected according to the support, the molecule to be fixed and the bond's  
25 strength properties which are desired for the targeted application.

This fixation may be direct or indirect.

Documents 1 to 10 mentioned below are detailed in the references at the end of this specification.

30 For example, according to the invention, when the support is a silica support, a functionalization

treatment of the silica support may be performed before fixing the first molecule, so as to modify the surface of the support in order to fix reactive chemical groups thereon, which will allow the first molecule to be  
5 fixed. Such a treatment is described in Example 1 below, but a great number of other examples will be found in the specialized literature, such as Pease et al. (Document 9), Guo et al. (Document 4), Maskos et al. (Document 6) etc. As stated earlier, silica is not  
10 the only possible support and each support will undergo the surface treatment which is suitable for it. To illustrate this on a polypropylene film, for example, reference will be made to Matson et al. (Document 7).

The reactive chemical groups are generally amine  
15 groups such as those mentioned in Guo et al. (Document 4) or carboxylic groups such as those mentioned in Kohsaka et al. (Document 5), or epoxy groups such as those mentioned in Maskos et al. (Document 6), for which commercial coupling agents exist, which are  
20 efficient and easy to use (see the Pierce catalogue, for example).

Covalent coupling is not the only way for fixing the first molecule on its support. Passive adsorption widely used for fixing antibodies on polystyrene  
25 reaction wells or on microbeads such as described in Elaïssari et al. (Document 3), is often very effective, also see Balladur et al. (Document 1). More recent fixation techniques may also be contemplated, such as the formation of a Langmuir-Blodgett film in which are  
30 included lipid chains onto which the first molecule has been coupled chemically, see Noy et al. (Document 8);

and Cornell et al. (Document 2), or further the metal-chelate method, see Porath et al., 1975 (Document 10).

According to the invention, when the first molecule is fixed on the support, the following steps  
5 may be the aforementioned contacting step and washing step.

According to the invention, the contacting step is of course, performed under conditions which are favourable to said hybridization, i.e., and obviously  
10 for one skilled in the art, at a suitable pH, at a suitable temperature and in a suitable solution for enabling hybridization of nucleic acids. This solution is the solution to be tested.

According to the invention, the step for washing  
15 the support notably has the purpose of removing the molecules in the solution which have not reacted with the recognition molecules on the support, i.e. in the above example, the nucleic acid molecules of the solution which are not hybridized to the nucleic acid  
20 molecules fixed on the support. A strong background noise level which would be generated by said molecules non-hybridized and not bound to the support may thus be avoided during the measurement.

Of course, the washing of the support on which the  
25 molecules are fixed, should be a mild wash which does not denaturate the nucleic acids involved in the hybridizations, does not destroy said formed hybridizations and does not release the first molecules fixed on the support. A washing example is given in the  
30 examples below. With this washing step, it is possible

to obtain the measurement sample used for measuring the absorption by the selected photothermal method.

According to the method of the invention, when the selected photothermal method is a photothermal deflection method, the sample comprising nucleic acids for example, is illuminated with a light beam called a pump beam and the absorption of the pump beam by the sample is detected by refraction or reflection of a probe beam.

10 The pump beam may for example be a pulsed laser or an intensity-modulated continuous laser. Preferably, it has an emission wavelength in the absorption range of the sample, for example in that of nucleic acids when the purpose is to detect hybridization of nucleic acids.

15 According to the invention, the probe beam preferably has a wavelength which is neither absorbed by the substrate nor by the molecules present.

According to the invention, the pump beam may be a beam from a laser selected from a 275 nm continuous argon laser or a quadrupled YAG laser with a wavelength of 266 nm. The pump beam may also be provided by a polychromatic source, for example, a mercury vapour lamp, if the emission spectrum of the source and its intensity provide sufficient signal for the detection.

25 The probe beam is directed to near the sample portion illuminated by the pump beam. Moreover, the probe beam may be identical with, or different from, the pump beam. The probe beam is preferably a laser beam, for example one from a 633 nm helium laser.

The relative position of the probe and pump beams define the configuration used. For example, the probe beam may cross one or more of the following media: the sample, for example the oligonucleotides, the solid support or the surrounding medium, for example a liquid or air.

The orientation of the probe beam with respect to the pump beam, may be selected at will, for example depending on the mechanical congestion and/or for optimizing the sensitivity by seeking maximum absorption according to the incidence angle.

According to the invention, the probe and pump beams may cross each other.

According to the invention, the probe and pump beams may be positioned in a transverse configuration or in a substantially colinear configuration. In the transverse configuration, the probe and pump beams cross each other, and are perpendicular to each other. This configuration is schematically illustrated in the appended figure 1a. In the substantially colinear configuration, the pump and probe beams cross each other, but are nearly colinear. The appended figure 1b is a schematic illustration of the colinear configuration.

In these figures, reference 1 shows the pump beam, reference 3 the probe beam in the transverse configuration, reference 5 the probe beam in the substantially colinear configuration and reference 7 the measurement sample positioned on the solid support.

Reflection or refraction of the probe beam may be detected by means of a multicomponent photodiode, for



example by a detector with two or four quadrants, by an array or a matrix, or by means of a single photodiode, either partly covered by a cover or knife, or only receiving a portion of the probe beam.

5        In the case of a single photodiode, another detector may be required in order to dissociate the changes in absorption of the sample, from the possible power changes of the pump beam.

10        Figure 2 is a schematic illustration of various configurations for detecting the deviation of the probe beam. In this figure, -A- schematically illustrates a bi-quadrant detector 9 and a spot 11 formed by the probe beam on the detector, -B- illustrates a four-quadrant detector, -C- illustrates a matrix detector, 15 -D- illustrates a single photodiode partly covered with a cover 13, and -E- illustrates an off-axis photodetector.

20        In order to achieve sufficient sensitivity, deflection of the probe beam induced by the absorption of a portion of the pump beam by the sample, for example by oligonucleotides, is preferably distinguished from the parasitic changes due to the environment, such as temperature changes in the laboratory. For this, the pump beam may be marked in 25 time either by modulation if it is a continuous beam, or by its pulsed operation. By controlling the modulation frequency and the possibility of obtaining a reference signal, the deflection due to the heating generated by partial absorption of the pump beam may be 30 detected preferentially.

Whatever the configuration of the beams used, the obtained information is local and relates to an area around the pump beam's impact point on the sample, comprising nucleic acids for example.

5       The size of this area may be set by experimental parameters such as the size of the pump beam at the impact point on the sample, or its modulation frequency, and by the thermal behaviour of the support, of the sample and of the ambient medium. This is  
10 notably due to heat diffusion in these various media.

As the information is local, the detection unit may be coupled with a system for displacing the solid support relatively to the pump beam. The whole then allows the deviation values of the probe beam to be  
15 compared from one point to another of the sample, in particular the signal may be illustrated as a mapping.

A point of the sample may for example, be understood as a molecular recognition area, i.e. a portion of the support which has, at its surface,  
20 molecules having a recognition property for a given type of target molecules. The solid support is therefore associated with a sample, itself consisting of several recognition points or areas. The supports are then functionalized supports.

25       In the case of nucleic acids, each of these recognition areas is associated with only one type of capture molecule which is preferably, but not in a limiting way, different from the other recognition areas which form the same sample. Thus, it is possible  
30 either to increase the size of each recognition area, or to have several recognition areas associated with

the same kind of capture molecule, and this with the purpose of increasing the signal to be detected.

When the signal is illustrated as a mapping, one then has the measurement of several recognition areas  
5 which correspond to several target molecules, either hybridized or not, on the captured molecules.

Further, one or more of these recognition areas may be assigned to one or several calibration samples as mentioned earlier.

10 When this is required, the deviation signal may be converted into an absorption value, for example via a reference sample or a calibration sample. This reference sample, the absorption of which is known and stable, may be the subject of a photothermal deflection  
15 measurement under the same experimental conditions as for the sample. With the obtained value, it is for example, possible to calculate a coefficient for converting the measured electrical signal into an absorption level.

20 Finally, when the photothermal method is a thermal lens method, an incident beam is used, which may be a laser beam selected from a 275 nm continuous argon laser, or a quadrupled YAG laser with a wavelength of 266 nm.

25 The thermal lens method is of interest because the assembly is simpler.

Indeed, in this case, there is only one laser which acts as a probe laser and pump laser. After interaction with the sample, the focussing point is  
30 changed. The measurement merely consists in measuring the change in light flux at the initial point. The pump

beam may be used either in transmission, i.e. through the sample, or in reflection.

The originality of the invention is therefore notably based on the fact that a photothermal technique  
5 has never been used for detecting molecular recognition for example of an oligonucleotide hybridization on a solid support. More generally, no method based on the measurement of a change in absorption has been used for this type of detection on a support.

10 The method of the present invention notably has the advantage of not requiring any labelling step or label. For example, it may advantageously be used for a diagnosis test by detecting hybridization of nucleic acids. This use will be illustrated in the application  
15 examples below.

Further, very small absorptions and changes in absorption, for example a few tenths of parts per million, may be detected.

The present invention also relates to a device for  
20 implementing the method of the invention, said device comprising the following components:

- means for positioning the solid support,
- means for illuminating said support,
- means for detecting the absorption of light by  
25 the sample borne by the support, when it is illuminated by said illuminating means, and
- means for positioning said illuminating means and said detecting means.

According to the invention, the means for  
30 positioning the support may be any means known for accurately displacing said support, for example

micrometric translation and rotation stages, for example of the MicroContrôle trade mark. These means may be motorized so as to notably provide automatization for a mapping.

5       According to the invention, the means for illuminating the sample and detecting the light absorption by the sample may notably be selected according to the photothermal method used, to the support and to the molecular recognition to be  
10 detected. The means for illuminating the sample may be a pump beam, for example, as defined earlier.

      When a photothermal deflection method is involved, the means for detecting the absorption may comprise a probe beam and means for detecting refraction or  
15 reflection of a probe beam. These means are described below and in the following examples.

      When a thermal lens method is involved, the detecting means may comprise a probe beam and a diaphragm placed at the focussing point.

20       According to the invention, the means for positioning the aforementioned illuminating and detecting means may be means such as those mentioned earlier for positioning the support.

      Other components of the invention and advantages  
25 will further become apparent upon reading the description and the examples which follow with reference to the appended drawings which are, of course, illustrative and non-limiting.

30   Short description of the Appendix and figures

The list of sequences illustrating example 4 is given in the appendix.

- Figure 1 is a schematic illustration of the transverse (figure 1a) and colinear (figure 1b) configurations of the pump and probe beams in a detection of photothermal deflection according to the method of the invention;

- figure 2 is a schematic illustration of different configurations for detecting the deviation of the probe beam;

- figure 3 is a schematic illustration of a measurement of absorption of a sample by the photothermal deflection method according to the invention;

- figure 4 is a diagram illustrating a device for implementing the method of the present invention;

- figure 5 is a graph illustrating results for the measurement of absorption of a sample consisting of nucleic acids, according to the method of the present invention;

- figure 6 is a mapping of a detection according to the method of the present invention, performed on a sample including two rows of oligonucleotide pins;

- figures 7a and 7b are histograms which represent the number of pixels of the mapping of figure 6.

### Examples

#### Example 1: Measurement method

The system used according to the invention is based on the photothermal deflection in a transverse configuration.

5 The appended figure 3 is a schematic illustration of the principle of a measurement of the absorption of a sample by the photothermal deflection method according to the invention.

10 In this figure, the pump beam 15 stems from a 275 nm continuous argon laser (COHERENT of the INOVA 40 (trade name) type), it is focussed on sample 7 by means of a spherical mirror (not shown), the spot diameter (not shown) is about 70 microns at the surface of sample 7. The wavelength of the pump beam is selected in order to provide detection of the hybridization of  
15 nucleic acids. The power of the pump beam is 300 mW at the laser output.

The probe beam 17 is a beam from a 633 nm helium-neon laser. The wavelength of this probe beam is indifferent. According to the invention, a better  
20 signal to noise ratio may be obtained with a wavelength far from that of the pump beam.

Detection of deflection is performed by means of a four quadrant detector -B- (see figure 2) followed by amplification and subtraction electronics (not shown).  
25 Reference 17a shows the probe beam deviated by photothermal deflection. The  $\theta$  angle shows the pump beam's incidence angle with respect to the normal 20 to the sample (shown in mixed lines).

An interference filter (not shown) which selects  
30 the wavelength of the probe beam may be placed in front of the four quadrant detector in order to avoid the

influence of parasitic light from the modulated pump beam.

In the device of the present invention, the probe laser, the four quadrant detector and the associated  
5 electronics may form an integral part of a commercial measurement cell, such as one from ALIS. The signal from this cell is sent to a synchronous detection stage.

The pump beam may be modulated by means of a  
10 mechanical slotted disc, also called a mechanical chopper hereafter, the frequency of which is adjustable. The control signal of the chopper is used as a reference for synchronous detection. The frequency is 157 Hz. The measured signal is obtained at the  
15 output of the synchronous detection stage (amplitude of the deviation signal at the pump beam's modulation frequency).

The positioning of the sample and of both beams relatively to each other, is provided by translation  
20 and rotation stages (Micro-Contrôle trade name), of which some are motorized in order to provide automatization for a mapping, for example of a biochip and in certain adjustment phases. The adjustments are automatically performed in order to maximize the  
25 deflection signal in a plane orthogonal to the sample containing the probe beam. During mappings, if required, corrective displacement is performed in a direction orthogonal to the scanning axes for the mapping in order to guarantee that correct relative  
30 positioning is maintained during the mapping. This corrective displacement is automatically determined in



a preliminary measurement step. The incidence angle of the pump beam with respect to the normal to the sample and the orientation of the cell with respect to the sample may be adjustable. The relative position and  
5 orientations of the probe and pump beams may also be adjustable independently.

A diagram of a device according to the invention is illustrated on the appended figure 4. In this figure, a shutter, not shown in the diagram, enables  
10 the pump beam to be cut off during the displacement phases and to be restored during a well-determined time interval after a selected waiting period for allowing the assembly to stabilize after displacement. Reference  
19 shows a 275 nm argon laser, reference 21 shows  
15 mirrors for positioning the laser beam, reference 23 shows a mechanical chopper, reference 25 the laser beam after its passing through the chopper, reference 27 a focussing mirror and reference 31 the measurement sample.

20 Reference 34 forms the measurement cell in which are integrated the probe laser 32 and the four quadrant diode 33.

Repeatability of the positioning of the sample may be provided by an autocollimating telescope for  
25 example, which is not shown in the diagram. The whole measuring device may be driven by a workstation which controls the displacements and acquires deviation signals in two orthogonal directions.

In this embodiment, the deviation is measured  
30 along a direction parallel to the plane of the sample and along a direction orthogonal to the latter. The

latter measurement is what forms the useful signal. The electronic signal provided by the synchronous detection stage may be used as such by comparison from one point to another of the sample.

5        It may also be converted into an absorption value by performing a reference measurement on a sample supposed to be stable over time and under a laser flux, the absorption of which is measurable on the spectrophotometer and is located in the linearity range  
10      of the photothermal deflection measurement bench.

#### Example 2: Preparation of functionalized supports

The molecules chosen in this example are nucleic acids, in particular oligonucleotides.

15        The production of thin biological layers to form the measuring sample according to the method of the present invention can for example include two steps:

- 1)    Functionalization of the substrate, and
- 2)    Grafting of the oligonucleotides.

20

#### Functionalization of the substrate

The support chosen is silica. Since the oligonucleotides are not able to establish covalent bonding with this type of material, the latter is  
25      functionalized. Functionalization of the support has the goal of modifying the surface of the substrate in order to introduce reactive groups into it that will enable grafting of the oligonucleotides.

This step requires, for example, a first treatment  
30      of the support for example by a sulphochromic mixture than silanization. The treatment with the sulphochromic

mixture may be carried out by means of a saturated solution of chromium oxide in 95% sulphuric acid. Its objective is to remove organic contaminants present on the support and to create silanol groups. The silanization is then carried out by standard silanization techniques, for example, by incubation of the support in a toluene solution, 1% aminopropyldimethylethoxysilane (AMPMES). During this step, the silanes react with the silanol groups created during the treatment with sulphochromic mixture. The formation of a layer of silane carrying amine groups results from this, on which it is possible to graft oligonucleotides.

#### 15 Grafting of the oligonucleotides

The oligonucleotides that form the capture molecules are grafted on the support either directly or through an avidin molecule.

In this latter case, a molecule of avidin is previously grafted on the silane through a coupling agent, phenylene diisothiocyanate (PDC). Avidin presents a strong affinity for a small molecule: biotin. Therefore, it can recognize and very strongly fix an oligonucleotide carrier of a biotin. Therefore, the support is incubated in a solution of 10% dimethylformamide/pyridine 0.2% PDC. After washing and drying the support, avidin is deposited in the form of drops several millimetres in diameter on the support. The carrier oligonucleotide of the biotin is deposited in the same place.

### Example 3: Use of functionalized supports

This step consists of carrying out hybridization of nucleic acids or fragments of them, which form the target molecules present in the solution to be tested.

5 It consists essentially of two steps:

1) Hybridization of the nucleic acids (in the experiment described, a complementary oligonucleotide), and

2) Washing non hybridized nucleic acids.

10 Of course, prior to these steps and in the specific case of nucleic acids, it may be required to carry out other preparatory steps to obtain the solution to be tested. These steps may be steps of extraction, amplification and cleavage.

15

### Extraction

This extraction is carried out in an entirely standard manner. In fact, any DNA extraction technique may be used, making it possible to obtain material  
20 capable of being amplified later by an amplification procedure. These cell lysis techniques, with extraction, then purification of nucleic acids are usually those recommended for genetic analyses, or rapid techniques using commercial products such as  
25 QIAmp Blood Kit (Registered trademark) from QIAGEN S.A.

### Amplification

Thus, it may be wise to increase the number of target molecules by amplifying the signal. Very  
30 numerous amplification techniques exist. The state of the art describes methods enabling amplification of the

nucleotide sequences using specific primers of sequences to be amplified. Thus, a fragment of nucleic acid of interest may be amplified within a preparation of nucleic acids. Numerous techniques use  
5 oligonucleotides complementary to the target sequence acting as primers for elongation by a polymerase.

For amplification of DNA, there is PCR (Polymerase Chain Reaction) such as described in the patents US-A-4,683,195, US-A-4,683,202 and US-A-4,800,159, LCR  
10 (Ligase Chain Reaction) explained for example in the patent application EP-A-0.201.184 or the RCR (Repair Chain Reaction) described in the patent application WO-A-90/01069.

For amplification of RNA, several techniques have  
15 also been described in different documents. These techniques are the following:

- 3SR (Self Sustained Sequence Replication) with the patent application WO-A-90/06995,
- NASBA (Nucleic Acid Sequence-Based  
20 Amplification) with the patent application WO-A-91/02818,
- SPSR (Single Primer Sequence Replication) with the patent US-A-5,194,370, and
- TMA (Transcription Mediated Amplification) with  
25 the patent US-A-5,399,491.

### Cleavage

Cleavage may also be wise because the product of the amplifications may be formed of nucleic acids that  
30 are large in size. Thus, when such target nucleic acids are hybridized on capture molecules, the duplexes

formed after hybridization with the target nucleic acids are not very stable. This is also the case when the polynucleotides are used as detection probes. The reasons may be due to the steric inhibition or to the  
5 lack of specificity between the capture molecule that has been synthesized and its target molecule that is not necessarily of the same size. Therefore, there is going to be a quantitative and qualitative loss of the signal.

10 The steric inhibition may be, not only because of the length of the nucleic acid, but also the existence or retention of the secondary structures. Cleavage enables these structures to be destroyed and thus optimizes hybridization. This steric inhibition plays a  
15 particularly important role in the case of hybridization on the surfaces containing capture probes in high density, for example the DNA chips developed by the Affymetrix company ("Accessing Genetic Information with High-Density DNA arrays", M. Shee et al., Science,  
20 274, 610-614. "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", A. Caviani Pease et al., Proc. Natl. Sci. USA, 1994, 91, 5022-5026). In this technology, the capture probes are generally of reduced size, around twenty nucleotides.

25 Where it concerns cleavage of nucleic acids, numerous methods are described in the state of the art. Firstly, cleavage may be enzymatic, that is, the fragmentation of nucleic acids may be carried out by nucleases (DNases or RNases). Then fragments small in  
30 size are created with 3'-OH, 5'-OH, 3'-phosphate, 5'-phosphate ends.

Secondly, cleavage may be chemical. For example, in the case of the DNA, depurination or depyrimidination of the DNA may be carried out, which are then cleaved in the presence of a base by a mechanism called " $\beta$ -elimination". The cleavage of the DNA may be carried out by mechanisms of oxidation, alkylation, the addition of free radicals, among others. To cleave the RNA, metal cations are used, often combined with organic molecules used as chemical catalysts, for example, imidazole. This cleavage is preferentially carried out in alkaline medium and creates fragments with 3'-phosphate ends.

#### Hybridization

The support on which the oligonucleotides are grafted is then incubated in a solution containing the complementary oligonucleotide for example a solution of 6X SSPE + 0.05% Triton X-100 + 20 nM target; 30 min at 35°C.

20

#### Washing the nonhybridized nucleic acids

After hybridization, the nucleic acids that are not hybridized are removed by washing in the same solution, 6X SSPE + 0.05% Triton-X.

Just before the detection according to the method of the present invention, the samples are taken out of their washing solution, passed rapidly under water to remove the buffer while taking care not to "dehybridize" the nucleic acids, and dried in the air.

30

#### Results

Mapping is carried out on the sample including two rows of oligonucleotide pins. Each pin is approximately three millimetres in diameter. The pins of the lower row include 32mer oligonucleotides hybridized by their complementary while those in the upper row include another 32mer oligonucleotide, not complementary. The mapping step is 250 microns.

The measurement of time is 5 seconds per point including one second before opening the obturator. The measuring point is therefore illuminated for 4 seconds. The measurements are carried out as rapidly as possible during this time. The time delay aimed at between each measurement is a tenth of a second. Therefore, at each measurement point, a signal is provided depending on the time. The speed of the variation of the signal according to time is represented by the curve in the attached figure 5.

In this figure on the ordinate, S represents the signal in absorbance unit and on the abscissa, t represents the time in seconds.

The signal includes a period of background noise, before opening the obturator followed by a rapid increase after opening. When a maximum is reached, the measured signal lowers again, with that expressing the change of the sample at the measuring point. To compare the signals obtained at each point of the mapping, it is preferable to extract from each signal a value that could be displayed in mapping form. This value for example may be the measured maximum or the value at a given time measured. It is also possible to adjust a well-chosen function for each temporal signal and



choose as representative value one of the parameters of adjustment of the function or the maximum of the latter. After this treatment phase, the result is displayed in mapping form.

5 Mapping that we have obtained experimentally is given in figure 6 in the appendix. It concerns maxima of the signal measured at each point of the mapping, maxima having taken place for  $t$  near 1.5 seconds. On this mapping, the oligonucleotides pins that may or may not be hybridized are perfectly distinguished from the background in which the absorption is very low. The pins of the right column, clear blue in colour on the mapping, have a lower absorption than those of the left column, green to yellow in colour on the mapping; the black rectangles correspond to nonmapped zones, because there had been a manual shift of the support during acquisition of the mapping to better see the pins of the right column. The observation of the mapping is therefore sufficient to determine if an oligonucleotide pin is hybridized or not.

20 Histograms of figures 7a and 7b in the appendix represent the number of pixels of the mapping (ordinate axis) for a given signal intensity (abscissa axis) on two different scales for the ordinates. Three modes are clearly seen to appear, corresponding to the absorption of the background, nonhybridized oligonucleotides, and hybridized oligonucleotides. These modes are well separated which enables use of image treatment methods enabling automatic recognition of the pins that may or may not be hybridized. A simple thresholding for example, makes it possible to only retain the

hybridized pins and some absorbing points easily distinguished from measuring pins.

Example 4: Diagnostic test

5       An important part of the genetic component of the susceptibility to rheumatoid arthritis was able to be associated with the HLA-DRB genes, coding for the b chain of the HLA-DR molecules involved in the presentation of the peptides to the T lymphocytes, pivotal function at the core of mechanisms of regulation of the immune response. More precisely, it has been shown that the presence of a specific sequence of five amino acids, corresponding to positions 70 to 74 of the third hypervariable region of the HLA-DRb1 molecules, was found for different alleles reported as being associated with rheumatoid arthritis. The involvement of this "shared epitope" corresponding to sequences QKRAA or QRRAA or RRRRAA (code with a letter for the amino acids) is from then on well documented.

20       However, if this group of DRB1\*04 alleles is associated with rheumatoid arthritis, all the alleles currently known (DRB1\*0401 to DRB1\*0427) are not necessarily associated with this disease. A result of this may be that if it is limited to a typing of the group of DRB1\*04 alleles according to the alleles present, one could obtain, beside true positives or true negatives, false positives which are going to unnecessarily alarm the physician and the patient.

30       In the case of a molecular biology technique (analysis of DRB1 alleles: results rendered according to the DRB1\*01 to DRB1\*10 nomenclature); the clinician

is essentially interested in the presence of the DRB1\*04 allele(s).

In case of results suggesting a predisposition to the disease, a second test is generally made using a molecular biology technique known as high resolution, known as subtyping of DR4, to clarify the DRB1\*04 allele (DRB1\*0401 to 0427 according to the official nomenclature in 1998), only the DRB1\*0401, 0404, 0405 and 0408 alleles being reported as being associated with the disease.

#### Extraction

Extraction is carried out by commercial products mentioned previously, such as QIAmp Blood Kit (registered trademark) of QIAGEN S.A.

#### Amplification

This amplification concerns the HLA-DR locus including the region of the exon 2 which corresponds to the codons 5 to 94 according to the official nomenclature of the HLA-DRB genes. Table 1 below describes the primers used during amplification by PCR of this previously described locus. It also gives all the physicochemical positions enabling this amplification to be made.

Table 1: Simultaneous amplification of the HLA-DR region of interest

|                         |   |
|-------------------------|---|
| Primers                 | <ul style="list-style-type: none"> <li>- P1(5'-DR primer): CCG GAT CCT TCG TGT CCC CAC AGC ACG (5'&gt;3')</li> <li>- P2 (3'-DR primer): TCG CCG CTG CAC TGT GAA G (5'&gt;3')</li> </ul>   |
| Reaction mixture        | <ul style="list-style-type: none"> <li>- buffer 10X TEMAG (*): 10 µL</li> <li>- dNTPs (20 mM): 1 µL (0.2 mM final)</li> <li>- P1 (30 µM): 0.8 µL (0.25 µM final)</li> <li>- P2 (30 µM): 0.8 µL (0.25 µM final)</li> <li>- AmpliTaq (5 U/µL): 0.5 µL (2.5 U)</li> <li>- DNA: 100-500 ng</li> <li>- H<sub>2</sub>O: QSP 100 µL</li> </ul> |
| Amplification programme | (5 min at 96°C) + 10 x (10 sec at 98°C + 30 sec at 65°C + 30 sec at 72°C) + 30 x (20 sec at 96°C + 30 sec at 65°C + 30 sec at 72°C)   |

(\*): Buffer 10X TEMAG: 500 mM Tris-HCl pH 8.8, 150 mM ammonium sulphate, 15 mM MgCl<sub>2</sub>, 500 µM EDTA, 0.1% gelatine

In this example the distance separating the two sources P1 and P2 is chosen to be sufficiently short so as not to have cleavage carried out. Of course, if the amplicons produced require it, this fragmentation of the nucleic acids may be carried out according to the means and conditions explained above.

#### Preparation of the functionalized supports

To be able to make a study of genetic predisposition to rheumatoid arthritis, there is reason to use a group of hybridization reactions using a set of oligonucleotide probes enabling the precise analysis of HLA-DRB1 and HLA-B\*27 alleles or groups of alleles. Table 2 describes the group of probes that is used for

detection of these two diseases. The instructions that are given from the left to the right are the following:

- the reference of the assigned probe in HLA nomenclature,
- 5        - the assigned number of the sequence in this document,
- the HLA gene concerned,
- the sequence forming this probe, and
- the localization of the codons (three
- 10 nucleotides) on the HLA genes

Table 2: Oligonucleotide probes

| Probe | SEQ<br>NO | ID | HLA<br>gene | Sequence (5'>3')                                   | Localization<br>(codons) |
|-------|-----------|----|-------------|--|--------------------------|
| C+    | 1         |    | DR          | TTC GAC AGC GAC GTG GGG                            | 40-45                    |
| C-    | 2         |    | -           | TAT GAA ACT TAT GGG GAT<br>AC                      | -                        |
| 4     | 3         |    | DR          | GAT ACT TCT ATC ACC A                              | 29-34                    |
| QK71  | 4         |    | DR          | GAG CAG AAI CGG ICC<br>GAG CAG AAG CGG GCC         | 69-73                    |
| IDE71 | 5         |    | DR          | CTG GAA GAC GAI CGG<br>CTG GAA GAC GAG CGG         | 68-72                    |
| E74   | 6         |    | DR          | AGC AIA IGC IGG ICI AII<br>AGC AGA GGC GGG CCG AGG | 69-75                    |
| QR71  | 7         |    | DR          | CAG AGG CGI GII ICI GTG<br>CAG AGG CGG GCC GCG GTG | 70-75                    |
| S57   | 8         |    | DR          | GCC TAG CGC CGA GTA                                | 55-60                    |
| 1     | 11        |    | DR          | TGG CAG CTT AAG TTT GAA                            | 9-14                     |
| 52    | 12        |    | DR          | TAC TCT ACG TCT GAG T                              | 10-15                    |
| 2     | 13        |    | DR          | CAG CCT AAG AGG GAG TG                             | 10-15                    |
| 7+9   | 14        |    | DR          | IAG GTI GAC AIC GTG TGC<br>CAG GTG GAC ACC GTG TGC | 74-79                    |
| 10    | 15        |    | DR          | GGA GGA GGT TAA GTT                                | 8-13                     |
| 8+12  | 16        |    | DR          | CTC TAC GGG IGA GT<br>CTC TAC GGG TGA GT           | 10-15                    |

|   |    |    |  |       |
|---|----|----|--|-------|
| 3 | 19 | DR | CCG GGT GGA CAA CIA C<br>CCG GGT GGA CAA CTA C | 73-78 |
|---|----|----|--|-------|

For certain probes, a second sequence in italics specifies the natural sequence, that is, only formed from the four nucleotides adenosine (A), thymine (T),  
 5 guanine (G) and cytosine (C). The other sequences have the same nucleotides except for the substitution of certain ones by different nucleotides. In the present case, it is inosine. The use of the inosines enables improvement again of the specificity of the probes with  
 10 respect to the sequences with which they are going to be hybridized. The specificity of the capture probes is clearly specified in Table 3 below.

15 Table 3: Principal specificities of the molecules or capture probes

| Probe | SEQ<br>ID<br>NO | Specificity   |
|-------|-----------------|---|
| C+    | 1               | All the DRB1*   |
| C-    | 2               | None  |
| 4     | 3               | DRB1*04   |
| QK71  | 4               | DRB1*04 allele possessing the QKRAA unit corresponding to the shared epitope                              |
| IDE71 | 5               | DRB1*0402   |
| E74   | 6               | DRB1*0403, 0406 and 0407  |
| QR71  | 7               | DRB1*0101, 0404, 0405, 0408 and 1402 allele possessing the unit QRRAA corresponding to the shared epitope |
| S57   | 8               | DRB1*0405   |

|      |    |                      |
|------|----|----------------------|
| 1    | 9  | DRB1*01              |
| 52   | 10 | DRB1*03,11,13 and 14 |
| 2    | 11 | DRB1*02              |
| 7+9  | 12 | DRB1*07 and 09       |
| 10   | 13 | DRB1*10              |
| 3    | 14 | DRB1*03              |
| 8+12 | 15 | DRB1*08 and 12       |

These probes are next set up on the solid support as mentioned previously. Of course, to facilitate the later analysis, it is appropriate to position each type of probe on a point or recognition zone.

In the present case, fifteen different recognition zones are required, by including the controls, whether they are positive or negative. It is also possible to carry out other tests on the same solid support, for this, it is sufficient to increase the number of recognition zones.

Table 4: Organization of the different recognition zones on the solid support

| Recognition zones |             | Recognition zones |              |
|-------------------|-------------|-------------------|--------------|
| C+                | SEQ ID NO 1 | 1                 | SEQ ID NO 9  |
| C-                | SEQ ID NO 2 | 52                | SEQ ID NO 10 |
| 4                 | SEQ ID NO 3 | 2                 | SEQ ID NO 11 |
| QK71              | SEQ ID NO 4 | 7                 | SEQ ID NO 12 |
| IDE71             | SEQ ID NO 5 | 10                | SEQ ID NO 13 |
| E74               | SEQ ID NO 6 | 8+12              | SEQ ID NO 14 |
| QR71              | SEQ ID NO 7 | 3                 | SEQ ID NO 15 |
| S57               | SEQ ID NO 8 |                   |              |

There is a positive control (SEQ ID NO 1) which enables detection of all the alleles of the DRB1\* gene, which makes it possible to check that the amplification has clearly concerned the region of interest between  
5 the primers P1 and P2 described in Table 1. The negative control (SEQ ID NO 2) has no diagnostic objective. It is present only to fulfil certain standards. This sequence is absolutely not specific to HLA and corresponds to a random sequence not found in  
10 the HLA genes.

The SEQ ID NO 3 enables the typing of all the alleles that form the DRB1\*04 group. It enables the identification of all the DRB1\*04 alleles, alleles belonging to the group defined as group DR4 by the HLA  
15 typing techniques by serology. It concerns a probe with low resolution, that is, numerous alleles may be recognized by the latter.

As for the SEQ ID NO 4 to 8, they enable subtyping of some of the alleles which form the DRB1\*04 group, by  
20 specifying the allele(s) sharing a particular sequence. It concerns probes with high resolution, that is, some alleles, even only one, may be recognized by these probes.

All these probes are used for detecting the  
25 alleles possessing the shared epitope associated with the genetic predisposition to rheumatoid arthritis. More specifically, the probes SEQ ID NO 4 and 7 enable detection of the alleles associated with the susceptibility to rheumatoid arthritis, and the probes  
30 SEQ ID NO 5 and 6 enable detection of the alleles associated with the resistance to said rheumatoid



arthritis. The probe SEQ ID NO 8 enables confirmation of a DRB1\*0405 allele.

### Results

5        In the results explained below, we worked with solutions to be tested for which the characteristics were known, in order to be able to check if the results obtained with the analysis method according to the present invention are clearly in conformity with  
10 reality.

#### 1<sup>ST</sup> SOLUTION TO BE TESTED

Table 5 which follows shows the signal values obtained with the first solution to be tested in which  
15 we had subtracted the value of the signal of the probe SEQ ID NO 2 (negative control). These values more or less far from the zero value make it possible to deduce whether hybridization has taken place or not. The 0 value has been put for all values not being  
20 distinguished significantly from the value obtained for SEQ ID NO 2 (deviation less than 2 times the standard error at the mean calculated for the probe SEQ ID NO 2).

25    Table 5: Hybridization results obtained with the first solution to be tested

| Probe associated with the recognition zone | Signal (arbitrary unit) | +/- | Probe associated with the recognition zone | Signal (arbitrary unit) | +/- |
|--|-------------------------|-----|--|-------------------------|-----|
| SEQ ID NO 1                                | 3000                    | +   | SEQ ID NO 9                                | 0                       | -   |
| SEQ ID NO 2                                | -                       | -   | SEQ ID NO                                  | 0                       | -   |

|             |     |   |              |      |   |
|-------------|-----|---|--------------|------|---|
|             |     |   | 10           |      |   |
| SEQ ID NO 3 | 920 | + | SEQ ID NO 11 | 2100 | + |
| SEQ ID NO 4 | 260 | + | SEQ ID NO 12 | 0    | - |
| SEQ ID NO 5 | 0   | - | SEQ ID NO 13 | 0    | - |
| SEQ ID NO 6 | 0   | - | SEQ ID NO 14 | 0    | - |
| SEQ ID NO 7 | 0   | - | SEQ ID NO 15 | 0    | - |
| SEQ ID NO 8 | 0   | - |              |      |   |

The analysis of the HLA-DR shows that:

- the SEQ ID NO 1 probe is positive: the HLA-DR amplification and the hybridization test worked well,
- 5       - the probes SEQ ID NO 3 and SEQ ID NO 4 are positive: a DRB1\*0401 allele is present, and
- the probe SEQ ID NO 11 is positive: a DRB1\*02 allele is present.

10       In conclusion, an allele of susceptibility for rheumatoid arthritis (DRB1\*0401) is present, the second allele being DRB1\*02 which was proof of neutrality with respect to rheumatoid arthritis.

The HLA typing of the first sample was HLA-DRB1\*0401/1602.

15

#### 2<sup>ND</sup> SOLUTION TO BE TESTED

Table 6 which follows, shows the values of OD obtained with the second sample to be tested.

Table 6: Results of hybridization obtained with the second solution to be tested

| Probe associated with the recognition zone | Signal (arbitrary unit) | +/- | Probe associated with the recognition zone | Signal (arbitrary unit) | +/- |
|--|-------------------------|-----|--|-------------------------|-----|
| SEQ ID NO 1                                | 3000                    | +   | SEQ ID NO 9                                | 0                       | -   |
| SEQ ID NO 2                                | 0                       | -   | SEQ ID NO 10                               | 0                       | -   |
| SEQ ID NO 3                                | 310                     | +   | SEQ ID NO 11                               | 2700                    | +   |
| SEQ ID NO 4                                | 0                       | -   | SEQ ID NO 12                               | 0                       | -   |
| SEQ ID NO 5                                | 370                     | +   | SEQ ID NO 13                               | 0                       | -   |
| SEQ ID NO 6                                | 0                       | -   | SEQ ID NO 14                               | 0                       | -   |
| SEQ ID NO 7                                | 0                       | -   | SEQ ID NO 15                               | 0                       | -   |
| SEQ ID NO 8                                | 0                       | -   |  |                         |     |

There are four positive probes, which are:

- 5        - the SEQ ID NO 1 probe: the HLA-DR amplification and the hybridization test worked well
- the probe SEQ ID NO 3: at least a DRB1\*04 allele is present
- the probe SEQ ID NO 5: a DRB1\*0402 allele is present , and
- 10       - the probe SEQ ID NO 11: a DRB1\*02 allele is present.

Therefore, it concerns two DR4 alleles not involved in the genetic susceptibility to rheumatoid arthritis, DRB1\*0402 and DRB1\*02.

The HLA typing of this third sample was HLA-  
5 DRB1\*0402/02.

### References

Doc. 1:

- Balladur, V., Theretz, A., and Mandrand, B.  
 5 Determination of the Main Forces Driving DNA  
 Oligonucleotide Adsorption onto Aminated Silica Wafers.  
*J. Colloid Interface Sci* 194 (2): 408-418, 1997.

Doc. 2:

- 10 Cornell, B.A., Braach-Maksvytis, V.L.B., King,  
 L.G., Osman, P.D.J., Raguse, B., Wieczorek, L., and  
 Pace, R.J. A biosensor that uses ion-channel switches.  
*Nature* 387: 580-583, 1997.

15 Doc. 3:

- Elaïssari, A., Cros, P., Pichot, C., Laurent V.,  
 and Mandrand, B. Adsorption of oligonucleotides onto  
 negatively and positively charged latex particles.  
*Colloids and Surfaces* 83: 25-31, 1994.

20

Doc. 4:

- Guo, Z., Guilfoyle, A., Thiel, A.J., Wang, R., and  
 Smith, L.M. Direct fluorescence analysis of genetic  
 polymorphisms by hybridization with oligonucleotide  
 25 arrays on glass supports. *Nucl. Acids Res.* 22 (24):  
 5456-5465, 1994.

Doc. 5:

- Kohsaka, H., Taniguchi, A., Richman, D.D., and  
 30 Carson, D.A. Microtiter format gene quantification by  
 covalent capture of competitive PCR products:

application to HIV-1 detection. *Nucl. Acids Res.* 21(15):3469-3472, 1993.

Doc. 6:

- 5       Maskos, U. and Southern, E.M. Oligonucleotide hybridisations on glass supports: a novel linker for oligonucleotide synthesis and hybridisation properties of oligonucleotides synthesised in situ. *Nucl. Acids Res.* 20(7):1679-1684, 1992.

10

Doc. 7:

- Matson, R.S., Rampal, J.B., and Coassin, P.J. Biopolymer synthesis on polypropylene supports - I. Oligonucleotides. *Analytical Biochemistry* 217:306-310, 15   1994.

Doc. 8:

- Noy, A., Vezenov, D.V., Kayyem, J.F., Meade, T.J., and Lieber, C.M. Stretching and breaking duplex DNA by 20   chemical force microscopy. *Chem. Biol.* 4(7):519-527, 1997.

Doc. 9:

- Pease, A.C., Solas, D., Sullivan, E.J., Cronin, 25   M.T., Holmes, C.P., and Fodor, S.P. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. *Proceedings of the National Academy of Sciences USA* 91:5022-5026, 1994.

- 30   Doc. 10:

Porath, J., Carlsson, J., Olsson, T., and Belfrage, G.  
Metal chelate affinity chromatography, a new approach  
to protein fractionation. *Nature* 258(5536):598-599,  
1975.

APPENDIX  
List of sequences

(1) GENERAL INFORMATION:

5 (i) APPLICANT:

(A) NAME: BIOMERIEUX S.A.

(B) STREET: Chemin de l'Orme

(C) CITY: Marcy-l'Etoile

(E) COUNTRY: France

10 (F) POSTAL CODE: 69280

(G) TELEPHONE: (33) 78.87.20.00

(H) FAX: (33) 78.87.20.90

(ii) TITLE OF THE INVENTION: Method of analysis of  
genetic predisposition of a patient to at  
15 least one genetic disease

(iii) NUMBER OF SEQUENCES: 19

(iv) FORM DECODABLE BY COMPUTER:

(A) TYPE OF SUPPORT: Floppy disk

(B) COMPUTER: IBM PC compatible

20 (C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, version  
#1.30 (OEB)

(2) INFORMATION ON SEQ ID NO 1:

25 (i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 18 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

30 (ix) CHARACTERISTICS:



(D) OTHER INFORMATION: sequence originated  
from HLA DR

(iv) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 1  
TTCGACAGCG ACGTGGGG

5 10

(3) INFORMATION ON SEQ ID NO 2:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 20 nucleotides

10 (B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY: primer

15 (D) OTHER INFORMATION:

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 2  
TATGAAACTT ATGGGGATAC

10 20

20(4) INFORMATION ON SEQ ID NO 3:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 16 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

25 (iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

30 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 3  
GATACTTCTA TCACCA

10

## (5) INFORMATION ON SEQ ID NO 4:

## (i) CHARACTERISTICS OF THE SEQUENCE:

5 (A) LENGTH: 15 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

## (ix) CHARACTERISTICS:

10 (A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

(iv) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 4

GAGCAGAAIC GGICC

15 10

## (6) INFORMATION ON SEQ ID NO 5:

## (i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 15 nucleotides

20 (B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

## (ix) CHARACTERISTICS:

(A) NAME/KEY:

25 (D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 5

CTGGAAGACG AICGG

10

30

## ((7) INFORMATION ON SEQ ID NO 6:

(i) CHARACTERISTICS OF THE SEQUENCE:  
    (A) LENGTH: 18 nucleotides  
    (B) TYPE: nucleic acid  
(ii) TYPE OF MOLECULE: nucleic acid  
5 (iii) HYPOTHETICAL: no  
(ix) CHARACTERISTICS:  
    (A) NAME/KEY: primer  
    (D) OTHER INFORMATION: sequence originated  
            from HLA DR  
10 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 6  
    AGCAIAIGCI GGICIAII  
    10

(8) INFORMATION ON SEQ ID NO 7:  
15 (i) CHARACTERISTICS OF THE SEQUENCE:  
    (A) LENGTH: 18 nucleotides  
    (B) TYPE: nucleic acid  
(ii) TYPE OF MOLECULE: nucleic acid  
(iii) HYPOTHETICAL: no  
20 (ix) CHARACTERISTICS:  
    (A) NAME/KEY:  
    (D) OTHER INFORMATION: sequence originated  
            from HLA DR  
    (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 7  
25 CAGAGGCGIG IIICIGTG  
    10

(9) INFORMATION ON SEQ ID NO 8:  
(i) CHARACTERISTICS OF THE SEQUENCE:  
30 (A) LENGTH: 15 nucleotides  
    (B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

5 (D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 8

GCCTAGCGCC GAGTA

10

10

(12) INFORMATION ON SEQ ID NO 9:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 18 nucleotides

(B) TYPE: nucleic acid

15 (ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
20 from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 11

TGGCAGCTTA AGTTTGAA

10

25(13) INFORMATION ON SEQ ID NO 10:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 16 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

30 (iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 12

5 TACTCTACGT CTGAGT

10

((14) INFORMATION ON SEQ ID NO 11:

(i) CHARACTERISTICS OF THE SEQUENCE:

10 (A) LENGTH: 17 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

15 (A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 13

CAGCCTAAGA GGGAGTG

20

10

((15) INFORMATION ON SEQ ID NO 12:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 18 nucleotides

25 (B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

30 (D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 14  
IAGGTIGACA ICGTGTGC

10

5(16) INFORMATION ON SEQ ID NO 13:

(i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 15 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

10 (iii) HYPOTHETICAL: no

(ix) CHARACTERISTICS:

(A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

15 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 15  
GGAGGAGGTT AAGTT

10

(17) INFORMATION ON SEQ ID NO 14:

20 (i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 14 nucleotides

(B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

25 (ix) CHARACTERISTICS:

(A) NAME/KEY:

(D) OTHER INFORMATION: sequence originated  
from HLA DR

(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 16  
30 CTCTACGGGI GAGT

10

## (18) INFORMATION ON SEQ ID NO 15:

## (i) CHARACTERISTICS OF THE SEQUENCE:

(A) LENGTH: 16 nucleotides

5 (B) TYPE: nucleic acid

(ii) TYPE OF MOLECULE: nucleic acid

(iii) HYPOTHETICAL: no

## (ix) CHARACTERISTICS:

(A) NAME/KEY:

10 (D) OTHER INFORMATION: sequence originated  
from HLA DR

## (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO 19

CCGGGTGGAC AACIAC

10

CLAIMS

1. Detection method of a molecular recognition reaction between a first molecule fixed on a support and a second molecule present in a solution to be tested, without labelling, in which the detection is  
5 carried out by a photothermal method.

2. Detection method of a hybridization reaction of nucleic acids between a first and second molecule of nucleic acids, without labelling, consisting of the  
10 following steps:

- fixation of the first nucleic acid molecule on a solid support,

- contacting of the first nucleic acid molecule fixed on the solid support with a solution to be tested  
15 suspected of containing the second nucleic acid molecule, this latter being capable of being hybridized with said first molecule, the contacting being carried out under conditions favourable for said hybridization,

- washing of the solid support to isolate a  
20 detection sample formed from said first molecule fixed on the support and possibly said second molecule linked to said first molecule, and

- measuring the absorption of the sample by a photothermal method.

25

3. Method according to Claim 1 or 2, in which the photothermal method is a thermal lens method.



4. Method according to Claim 1 or 2, in which the photothermal method is a method of photothermal deflection in which the sample is illuminated by a pump beam and the absorption of the pump beam by a sample is  
5 detected by the refraction or the reflection of a probe beam.

5. Method according to Claim 4, in which the probe and pump beams cross each other.  
10

6. Method according to Claim 4, in which the probe and pump beams are in a transverse configuration or in an approximately collinear configuration.

7. Method according to any one of Claims 4 to 6, in which the pump beam is chosen from a pulsed laser, a continuous intensity-modulated laser or polychromatic light.  
15

8. Method according to any one of Claims 4 to 7, in which the refraction or the reflection of the probe beam is detected by means of a multielement photodiode or by means of a single photodiode receiving only part of the probe beam.  
20

9. Method according to any one of Claims 4 to 8, in which the pump beam is a beam from a laser chosen from a continuous argon laser at 275 nm, a quadrupled YAG laser with a wavelength of 266 nm or polychromatic  
25  
30 light.

10. Method according to any one of Claims 4 to 9, in which the probe beam has a wavelength that is not absorbed by the substrate or the molecules present.

5        11. Method according to Claim 3, in which an incident beam is used, said beam being a beam from a laser chosen from a continuous argon laser at 275 nm, a quadrupled YAG laser with a wavelength of 266 nm or polychromatic light.

10

12. Method according to any one of the preceding claims, comprising in addition a step for comparing the measurement of absorption of the sample with that of a control sample.

15

13. Use of method according to any one of Claims 1 to 12, for a test, a diagnosis or a detection of hybridization of nucleic acids.

20        14. Device for implementing the method according to any one of Claims 5 to 8, said device comprising the following elements:

- a means for positioning the support
- a means for illuminating the support
- 25        - a means for detecting the absorption of light by the sample brought by the support when it is illuminated by said illuminating means, and
- a means for positioning said illuminating means and said detecting means.

English translation of the amended sheets of  
International Preliminary Examination Report

CLAIMS

1. Detection method of a molecular recognition reaction between a first molecule fixed on a support and a second molecule present in a solution to be tested, characterized in that the detection of the  
5 molecular recognition reaction is carried out without labelling by a photothermal method.

2. Detection method of a hybridization reaction of nucleic acids between a first and second molecule of  
10 nucleic acids consisting of the following steps:

- fixation of the first nucleic acid molecule on a solid support,

- contacting of the first nucleic acid molecule fixed on the solid support with a solution to be tested  
15 suspected of containing the second nucleic acid molecule, this latter being capable of being hybridized with said first molecule, the contacting being carried out under conditions favourable for said hybridization,

- washing of the solid support to isolate a  
20 detection sample formed from said first molecule fixed on the support and possibly said second molecule linked to said first molecule, and

- detection of the hybridization reaction,  
characterized in that the detection of the  
25 hybridization reaction is carried out without labelling by a photothermal method.

English translation of the amended sheets of  
International Preliminary Examination Report

9. Method according to any one of Claims 4 to 8,  
in which the pump beam is a beam from a laser chosen  
from a continuous argon laser at 275 nm, a quadrupled  
YAG laser with a wavelength of 266 nm or polychromatic  
5 light.

10. Method according to any one of Claims 4 to 9,  
in which the probe beam has a wavelength that is not  
absorbed by the substrate or the molecules present.  
10

11. Method according to Claim 3, in which an  
incident beam is used, said beam being a beam from a  
laser chosen from a continuous argon laser at 275 nm, a  
quadrupled YAG laser with a wavelength of 266 nm or  
15 polychromatic light.

12. Method according to any one of the preceding  
claims, comprising in addition a step for comparing the  
measurement of absorption of the sample with that of a  
20 control sample.

13. Use of method according to any one of Claims 1  
to 12, for a test, a diagnosis or a detection of  
hybridization of nucleic acids.